Future Medicinal Chemistry · 2017 · 23 citations · 52 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsDrug-target Interaction MappingEnzyme InhibitionFragment-based Drug DesignFragment-based OptimizationLigand-based DesignStructure-activity Relationship AnalysisAntibiotic DiscoveryFragment-based DiscoveryFragment-based SimilarityNovel Antibacterial Drug DiscoveryStatistical ValidationStructure-activity Relationship ModelingStructure-based Lead DiscoveryStructure-based Screening
AIM: FabI is a key enzyme in the fatty acid metabolism of Gram-positive bacteria such as Staphylococcus aureus and is an established drug target for known antibiotics such as triclosan. However, due to increasing antibacterial resistance, there is an urgent demand for new drug discovery. Recently, aminopyridine derivatives have been proposed as promising competitive inhibitors of FabI. METHODS: In the present study, holographic structure-activity relationship (HQSAR) analyses were employed for determining structural contributions of a series containing 105 FabI inhibitors. RESULTS & CONCLUSION: equal to 0.696 and 0.854, respectively) and could be further employed to generate fragment contribution maps. Then, final HQSAR model together with FabI active site information can be useful for designing novel bioactive ligands.
52
The PyMOL Molecular Graphics System
Warren L. DeLano · Medical Entomology and Zoology · 2002 · 18.1K citations
Alexander Golbraikh, Alexander Tropsha · Journal of Molecular Graphics and Modelling · 2002 · 3.7K citations